On the Record · Merck
Merck competitors, on the record
The companies whose own annual reports name Merck as a competitor, each with the sentence it appears in and the filing it came from.
Who Merck names
Merck’s annual reports for 2023 to 2025 describe its competition by kind of business and do not name competing companies.
Who names Merck
Companies whose own annual reports name Merck as a competitor.
Word for word“Merck KEYTRUDA U.S., Europe, Asia Pacific & China” 10-K for 2025
Word for word“There are several competitors that are marketing and/or developing antibodies against PD-1 and/or PDL-1 (some of which were approved in the relevant indications and commercialized before Libtayo), including Merck's Keytruda ® (pembrolizumab), Bristol-Myers Squibb's Opdivo ® (nivolumab), Roche's Tecentriq ® (atezolizumab), AstraZeneca's Imfinzi ® (durvalumab), and Sun Pharma's Unloxcyt ™ (cosibelimab).” 10-K for 2025
Word for word“Bristol-Myers Squibb's, or BMS's nivolumab and Merck's pembrolizumab are approved for the treatment of certain patients with relapsed or refractory classical Hodgkin lymphoma, and Acrotech Biopharma's pralatrexate and belinostat are approved for relapsed or refractory systemic anaplastic large cell lymphoma, or sALCL, among other T-cell lymphomas.” 10-K for 2022
Word for word“Our direct competitors in the PRC and global markets by product category include: • Hepatitis A: AIM Vaccine, IMBCAMS, Pukang Biological, CNBG (Domestic); GSK, Merck (International).” 20-F for 2025
Word for word“For example, Merck commercially launched Winrevair (sotatercept-csrk) in the United States in March 2024, which competes with our treprostinil-based products.” 10-K for 2025
Read from Merck’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.